Robust & reliable neoantigen prediction to empower the next generation cancer immunotherapies.
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines. The AI technology can be used to identify optimal antigen/epitope targets for infectious disease vaccines, truly personalized cancer vaccines & T cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy.
NEC OncoImmunity AS is a subsidiary of NEC Corporation, and is based in Oslo, Norway.
NEC OncoImmunity AS has assembled a growing and experienced multidisciplinary team of bioinformaticians, software-engineers and data scientists with machine-learning expertise.
A development environment deeply immersed in the combined scientific fields of bioinformatics, biotechnology, onco-immunology and data science